Skip to main content
IMUX
NASDAQ Life Sciences

Immunic's CALLIPER Phase 2 Misses Primary Endpoint; Progressive MS Phase 3 Planned for H1/2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$8.2
Mkt Cap
$108.337M
52W Low
$5.062
52W High
$17.43
52W Position info
62% above low
Off High info
53% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

IMUX sits 62% above its 52-week low of $5.062.

Summary

Immunic disclosed CALLIPER Phase 2 progressive MS data showing the primary brain-volume endpoint was not met (4.7% relative difference, P=0.78), while exploratory disability measures trended favorably. The company will advance a ~1,400-patient Phase 3 (PROTECT-MS) with first-patient-enrolled expected in H1/2027.


Key Events · Product Development and Regulatory · IMUX

  • CALLIPER Phase 2 Primary Endpoint Missed

    Annualized percent brain volume change at 30 months showed a 4.7% relative difference versus placebo (95% CI -0.285 to 0.379; P=0.78), so statistical significance was not achieved.

  • Exploratory Disability Signals Favor Drug

    24-week confirmed disability improvement hazard ratio was 2.44 (1.07-5.58), nominally significant, and the win ratio showed patients 1.5x more likely to have a beneficial disability outcome (nominal p=0.042).

  • Regional Atrophy Trends, Not Significant

    At 30 months, regional atrophy differences favored vidofludimus calcium at 15.7% for gray matter, 10.0% for cortical gray matter and 35.0% for thalamus, though statistical significance was not achieved.

  • PROTECT-MS Phase 3 Design Disclosed

    The Phase 3 trial targets roughly 1,400 patients with non-active SPMS or PPMS, uses confirmed disability worsening or the 9-hole peg test as the primary endpoint, and expects first-patient-enrolled in H1/2027.


Analysis · IMUX · Life Sciences

The progressive MS program is now quantified, and the headline is a miss: CALLIPER's primary endpoint — annualized percent brain volume change at 30 months — showed only a 4.7% relative difference versus placebo (P=0.78). What keeps the story alive is the exploratory layer: a nominally significant 24-week confirmed disability improvement hazard ratio of 2.44 and a 1.5x win ratio (nominal p=0.042), plus favorable trends in gray matter, cortical gray matter and thalamus atrophy that did not reach significance. Immunic is proceeding with PROTECT-MS, a ~1,400-patient Phase 3 in non-active SPMS and PPMS with first-patient-enrolled expected in H1/2027, so the progressive MS bet now rests on a disability endpoint rather than the imaging endpoint that failed. The near-term stock driver remains the relapsing MS ENSURE-1/ENSURE-2 top-line data expected in December 2026, with a targeted NDA submission in mid-2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMUX was trading at $8.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.3M. The 52-week trading range was $5.06 to $17.43. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMUX - Latest Insights

IMUX
Nov 13, 2026, 7:12 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.71
Real-time Price: $7.25 info
Change: -$0.460 (-6%) info
Market Cap: $117.359M info
IMUX
Sep 09, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.26
Real-time Price: $7.25 info
Change: -$6.01 (-45%) info
Market Cap: $117.359M info
IMUX
Aug 11, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.10
Real-time Price: $7.25 info
Change: -$6.85 (-49%) info
Market Cap: $117.359M info
IMUX
Aug 11, 2026, 6:59 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.10
Real-time Price: $7.25 info
Change: -$6.85 (-49%) info
Market Cap: $117.359M info
IMUX
Jul 14, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.60
Real-time Price: $7.25 info
Change: -$7.35 (-50%) info
Market Cap: $117.359M info